YUPELRI delivers a full 24 hours of efficacy in a single nebulized daily dose
YUPELRI was studied in two 12-week, randomized, double-blind, placebo-controlled, parallel-group confirmatory studies (Studies 1 and 2) to evaluate the efficacy of once-daily YUPELRI vs placebo in patients with moderate to very severe COPD1
Consistent improvement in FEV1 vs placebo over 24 hours on days 84/851,11

In Studies 1 and 2, serial spirometry was performed on a substudy population. Pooled results are shown.
Primary efficacy endpoint was change from baseline in trough (predose) FEV1 at day 85 vs placebo.
- In Studies 1 and 2, a prespecified exploratory analysis was performed. In Study 1, LS mean changes from baseline in FEV1 ranged from 55.8 mL to 240.4 mL in the YUPELRI group, and from -113.6 mL to 59.6 mL in the placebo group. In Study 2, LS mean changes from baseline in FEV1 ranged from 19.8 mL to 148.5 mL in the YUPELRI group, and from -176.4 mL to -13.0 mL in the placebo group11
YUPELRI delivers consistent control* over 12 weeks
Consistent improvements† in trough FEV1 over the 12-week study period1,11

Pooled data from Studies 1 and 2. Primary efficacy endpoint: change from baseline in trough (predose) FEV1 at day 85 vs placebo.
*In Study 1, LS mean change from baseline in trough FEV1 on day 85 was 127 mL (YUPELRI, n=189) and -19 mL (placebo, n=191), with a statistically significant difference vs placebo of 146 mL (P<.0001). In Study 2, LS mean change from baseline in trough FEV1 on day 85 was 102 mL (YUPELRI, n=181) and -45 mL (placebo, n=187), with a statistically significant difference of 147 mL (P<.0001).11
†The first measurement was taken at 2 weeks.
‡LS mean difference from placebo (SE) is 148.13 (16.782), pooled estimate adjusts the LS mean for placebo as well.11
Studies 1 and 2 patient characteristics1
- Mean age 64 years (range, 41-88 years)
- Mean smoking history of 53 pack-years; 48% current smokers
- Moderate to very severe COPD (mean post-bronchodilator % predicted FEV1 of 55%)
- 37% were on concomitant LABA or ICS/LABA therapy

COPD symptom improvement

Activities of daily living

Social interaction
- In Study 1, the SGRQ responder rate for the YUPELRI treatment arm on day 85 was 49% compared to 34% for placebo (odds ratio=2.11; 95% CI, 1.14-3.92)1§
- In Study 2, the SGRQ responder rate for the YUPELRI treatment arm was 45% compared to 39% for placebo (odds ratio=1.31; 95% CI, 0.72-2.38)1
- The clinical relevance of the above data is unknown